Robert Macgregor, MD
Neurology · Savannah, GANPI 1922201912
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Lilly USA, LLC at 47.1% of the total. Reporting peaked in 2020 at $13,461 and has fallen 65.5% since, to $4,640 in 2025. Among neurology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,693 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$23K
- AbbVie$3K
- EMD Serono, Inc.$2K
- Biogen$2K
- UCB, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $16K from 54 others
Across 85 payments — averaging $4161.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceuticals, Inc.$140K
- Vertex$121K
- Sage Therapeutics, LLC$45K
- Biohaven Pharmaceutical Holding Company Ltd.$25K
- Biogen$14K
- Teva Pharmaceuticals USA, Inc.$9K
What the payments were for
- Speaking & faculty fees$21,66644%
- Grants$440%
- Travel & lodging$5601%
- Food & beverage$26,81054%
- Education$1430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,224 in reported general payments places this provider in the 90th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 47 | $562,230 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 20 | $449,637 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $442,052 |
| EpidiolexCannabidiol (Cbd) | 47 | $299,401 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 23 | $150,680 |
| Kesimpta PenOfatumumab | 11 | $94,170 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $87,933 |
| Nurtec OdtRimegepant Sulfate | 59 | $72,359 |
| AptiomEslicarbazepine Acetate | 38 | $66,550 |
| RexultiBrexpiprazole | 29 | $65,492 |
| Aimovig AutoinjectorErenumab-Aooe | 56 | $54,043 |
| Wellbutrin XlBupropion Hcl | 12 | $47,162 |
| TrileptalOxcarbazepine | 23 | $45,184 |
| UbrelvyUbrogepant | 35 | $39,500 |
| QuliptaAtogepant | 22 | $31,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,239 | $562,23047 claims |
| CSL BehringPrivigen | $340 | $442,05216 claims |
| PfizerOctagam, Nurtec Odt | $794 | $160,29272 claims |
| AbbVieUbrelvy, Qulipta | $3,046 | $71,46257 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $170 | $65,49229 claims |
| SK Life Science, Inc.Xcopri | $914 | $24,86822 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $54 | $18,51212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 506 neurology providers in Georgia.
Other neurology in Savannah
- Victor RosenfeldSavannah$413K
- Brandi FleenorSavannah$47K
- Stephen DonahueSavannah$25K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.